S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:MYGN

Myriad Genetics (MYGN) Stock Forecast, Price & News

$21.97
+0.43 (+2.00%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$21.08
$22.01
50-Day Range
$19.68
$26.09
52-Week Range
$18.98
$36.95
Volume
427,970 shs
Average Volume
569,930 shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.57
30 days | 90 days | 365 days | Advanced Chart
Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

Myriad Genetics logo

About Myriad Genetics

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Headlines

Myriad Genetics Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MYGN
CUSIP
62855J10
Employees
2,400
Year Founded
1991

Sales & Book Value

Annual Sales
$690.60 million
Cash Flow
$0.48 per share
Book Value
$11.83 per share

Profitability

Net Income
$-27.20 million
Pretax Margin
-4.97%

Debt

Price-To-Earnings

Miscellaneous

Free Float
78,897,000
Market Cap
$1.77 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/22/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

685th out of 1,416 stocks

Diagnostic Substances Industry

11th out of 27 stocks

Analyst Opinion: 2.8Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

Is Myriad Genetics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Myriad Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View analyst ratings for Myriad Genetics
or view top-rated stocks.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Myriad Genetics
.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings data on Thursday, May, 5th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. The company had revenue of $164.90 million for the quarter, compared to analyst estimates of $156.09 million. Myriad Genetics had a negative trailing twelve-month return on equity of 2.75% and a negative net margin of 1.20%. Myriad Genetics's quarterly revenue was down 4.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.16) earnings per share.
View Myriad Genetics' earnings history
.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of 0-$0.20 for the period, compared to the consensus estimate of $0.08. The company issued revenue guidance of $670.00 million-$700.00 million, compared to the consensus revenue estimate of $684.40 million.

What price target have analysts set for MYGN?

3 equities research analysts have issued 12 month price targets for Myriad Genetics' shares. Their forecasts range from $23.00 to $35.00. On average, they expect Myriad Genetics' stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 32.0% from the stock's current price.
View analysts' price targets for Myriad Genetics
or view top-rated stocks among Wall Street analysts.

Who are Myriad Genetics' key executives?
Myriad Genetics' management team includes the following people:
  • Mr. Paul J. Diaz, CEO, Pres & Director (Age 60, Pay $2.92M)
  • Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 51, Pay $934.49k)
  • Ms. Nicole Lambert, COO & Pres of Myriad Genetic Laboratories (Age 48, Pay $825.23k) (LinkedIn Profile)
  • Mr. Mark S. Verratti, Chief Commercial Officer (Age 54, Pay $723.29k)
  • Dr. Kevin Richard Haas, Chief Technology Officer (Age 36)
  • Dr. Dale Muzzey Ph.D., Chief Scientific Officer (Age 42)
  • Mr. Scott Gleason, Sr. VP of Investor Relations (Age 43)
  • Mr. Nathan Smith, Sr. VP of Investor Relations & Treasury
  • Dr. Clivetty Martinez, Chief Compliance Officer
  • Ms. Pamela Wong, Chief Legal Officer (Age 54)
What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics CEO Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among Myriad Genetics' employees.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (18.42%), Vanguard Group Inc. (11.17%), Earnest Partners LLC (7.81%), Wellington Management Group LLP (6.34%), State Street Corp (5.22%) and Dimensional Fund Advisors LP (3.19%). Company insiders that own Myriad Genetics stock include Alexander Ford, Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee and S Louise Phanstiel.
View institutional ownership trends for Myriad Genetics
.

Which major investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Vanguard Group Inc., Invesco Ltd., Prudential Financial Inc., Citigroup Inc., Dimensional Fund Advisors LP, and First Trust Advisors LP. Company insiders that have sold Myriad Genetics company stock in the last year include Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Nicole Lambert, Richard Bryan Riggsbee, and S Louise Phanstiel.
View insider buying and selling activity for Myriad Genetics
or view top insider-selling stocks.

Which major investors are buying Myriad Genetics stock?

MYGN stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Polar Asset Management Partners Inc., BlackRock Inc., Sei Investments Co., Pinz Capital Management LP, JPMorgan Chase & Co., Renaissance Technologies LLC, and Glenview Capital Management LLC.
View insider buying and selling activity for Myriad Genetics
or or view top insider-buying stocks.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $21.97.

How much money does Myriad Genetics make?

Myriad Genetics has a market capitalization of $1.77 billion and generates $690.60 million in revenue each year. The company earns $-27.20 million in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does Myriad Genetics have?

Myriad Genetics employs 2,400 workers across the globe.

Does Myriad Genetics have any subsidiaries?

The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics B.V., Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics S.r.l., Myriad Neuroscience, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.

When was Myriad Genetics founded?

Myriad Genetics was founded in 1991.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is www.myriad.com.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at (801) 584-3600, via email at [email protected], or via fax at 801-584-3640.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.